Kalaris Therapeutics, Inc. (NASDAQ:KLRS) — Market Cap & Net Worth
Market Cap & Net Worth: Kalaris Therapeutics, Inc. (KLRS)
Kalaris Therapeutics, Inc. (NASDAQ:KLRS) has a market capitalization of $103.73 Million ($103.73 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19133 globally and #4352 in its home market, demonstrating a 11.38% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kalaris Therapeutics, Inc.'s stock price $4.55 by its total outstanding shares 23792278 (23.79 Million). Review debt load of Kalaris Therapeutics, Inc. to assess the company's total debt and financial obligations.
Kalaris Therapeutics, Inc. Market Cap History: 2025 to 2026
Kalaris Therapeutics, Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $200.81 Million to $108.25 Million (0.00% CAGR).
Index Memberships
Kalaris Therapeutics, Inc. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #541 of 976 |
Weight: Kalaris Therapeutics, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kalaris Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kalaris Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of KLRS by Market Capitalization
Companies near Kalaris Therapeutics, Inc. in the global market cap rankings as of June 19, 2026.
Key companies related to Kalaris Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Kalaris Therapeutics, Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, Kalaris Therapeutics, Inc.'s market cap moved from $200.81 Million to $ 108.25 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $108.25 Million | -46.09% |
| 2025 | $200.81 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Kalaris Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $103.73 Million USD |
| MoneyControl | $103.73 Million USD |
| MarketWatch | $103.73 Million USD |
| marketcap.company | $103.73 Million USD |
| Reuters | $103.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudativ… Read more